![The Promise of State-of-the-Art Sequencing Technologies for Cancer Screening](https://www.g2intelligence.com/wp-content/uploads/2022/12/Jan23.DTET_.NGS_.CancerScreeningDiagnostics-Header-iStock-1800x1250-1-1080x675.jpg)
The Promise of State-of-the-Art Sequencing Technologies for Cancer Screening
Circulating tumor DNA sequencing technologies are tackling the challenges of early cancer detection.
Circulating tumor DNA sequencing technologies are tackling the challenges of early cancer detection.
A new test targeting changes in serum proteins can detect breast cancer up to two years before the condition would normally be diagnosed.
The FDA recently confirmed that a new rule requiring healthcare providers to notify patients of their breast density status will be released in late 2022 or early 2023.
FDA confirms the new rule, which will update the Mammography Quality Standards Act, will publish before the end of 2022, or early 2023.
Recent study provides new details on how COVID-19 impacted cancer deaths in the US early in the pandemic and which groups were most affected.